MilliporeSigma Articles

  1. 4 Considerations For Overcoming Challenges In Gene Therapy Testing

    With continuously evolving gene therapy regulations and guidance and limited time during development for testing, here are four points to consider when planning product-release testing of your gene therapy product.

  2. The Importance Of Scalability In Viral Vectors

    Diseases that lack a cure, or even treatment, may be addressed with new gene therapeutic classes. This potential has spurred new investments in the drug development and commercialization space.

  3. Strategies For Ensuring Virus Bank Manufacturing Success

    Learn about the processes and best practices applied at a GMP facility to optimize the production of working virus seed stocks and master virus seed stocks.

  4. Perspectives Of Value-Driven, Integrated Solutions In Gene Therapy

    With an integrated solutions provider, you can leverage a comprehensive suite of advanced technologies and expertise that will facilitate your path to market and benefit you for the lifetime of your product.

  5. Viral Vectors: Are We There Yet?

    What must we do as an industry to continue the momentum of cell and gene therapies and ensure these revolutionary treatments become a reality for patients who need them?

  6. Viral Clearance Considerations For Adeno-Associated Virus (AAV) Vectors

    There is no one-size-fits-all model for AAV gene therapy products when it comes to viral clearance studies. Here, we address some of the questions concerning viral clearance studies for AAV vectors.